In addition, pembrolizumab is approved in the front-line setting for advanced NSCLC patients as monotherapy (for PD-L1 expression greater than 50%) or in combination with platinum based chemotherapy (regardless of PD-L1 expression). This evidence concerns the gene CD274 and non-small cell lung carcinoma.